CI vs. NVS
CI (The Cigna Group) and NVS (Novartis AG) are both stocks. Both are in the Healthcare sector — CI in Healthcare Plans, NVS in Drug Manufacturers - General. Over the past 10 years, CI returned 7.97%/yr vs 9.95%/yr for NVS. At a 0.27 correlation, their price movements are largely independent.
Performance
CI vs. NVS - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, CI achieves a 4.33% return, which is significantly lower than NVS's 11.78% return. Over the past 10 years, CI has underperformed NVS with an annualized return of 7.97%, while NVS has yielded a comparatively higher 9.95% annualized return.
CI
- 1D
- 0.88%
- 1M
- 1.67%
- 6M
- 5.49%
- YTD
- 4.33%
- 1Y
- -1.85%
- 3Y*
- 0.77%
- 5Y*
- 5.92%
- 10Y*
- 7.97%
- ALL TIME*
- 11.00%
NVS
- 1D
- -2.73%
- 1M
- 1.69%
- 6M
- 6.77%
- YTD
- 11.78%
- 1Y
- 34.89%
- 3Y*
- 16.47%
- 5Y*
- 14.79%
- 10Y*
- 9.95%
- ALL TIME*
- 8.95%
CI vs. NVS - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
CI The Cigna Group | 4.33% | 1.72% | -6.27% | -7.97% | 46.68% | 12.29% | 1.83% | 7.70% | -6.46% | 52.29% |
NVS Novartis AG | 11.78% | 46.95% | 0.02% | 16.14% | 8.06% | -3.65% | 3.34% | 13.92% | 5.95% | 19.42% |
Correlation
The correlation between CI and NVS is 0.28, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.28 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.29 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.33 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.29 |
Correlation (All Time) Calculated using the full available price history since Nov 7, 1996 | 0.27 |
Fundamentals
CI:
$75.11B
NVS:
$285.37B
CI:
$23.64
NVS:
$7.02
CI:
12.01
NVS:
21.31
CI:
0.69
NVS:
1.44
CI:
0.27
NVS:
5.15
CI:
1.78
NVS:
7.44
CI:
$277.94B
NVS:
$56.05B
CI:
$19.38B
NVS:
$42.19B
CI:
$10.03B
NVS:
$22.40B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
CI vs. NVS — Risk / Return Rank
CI
NVS
CI vs. NVS - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for The Cigna Group (CI) and Novartis AG (NVS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| CI | NVS | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.69 | ||
| Sortino ratioReturn per unit of downside risk | -2.16 | ||
| Omega ratioGain probability vs. loss probability | 1.02 | 1.28 | -0.26 |
| Calmar ratioReturn relative to maximum drawdown | -0.09 | 2.77 | -2.86 |
| Martin ratioReturn relative to average drawdown | -0.20 | 6.58 | -6.79 |
Loading charts...
Drawdowns
CI vs. NVS - Drawdown Comparison
The maximum CI drawdown since its inception was -84.34%, which is greater than NVS's maximum drawdown of -42.10%. Use the drawdown chart below to compare losses from any high point for CI and NVS.
Loading charts...
Drawdown Indicators
| CI | NVS | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -84.34% | -42.10% | -42.24% |
Max Drawdown (1Y)Largest decline over 1 year | -21.41% | -12.65% | -8.76% |
Max Drawdown (3Y)Largest decline over 3 years | -32.10% | -19.95% | -12.15% |
Max Drawdown (5Y)Largest decline over 5 years | -32.10% | -20.42% | -11.68% |
Max Drawdown (10Y)Largest decline over 10 years | -42.47% | -26.03% | -16.44% |
Current DrawdownCurrent decline from peak | -19.78% | -8.60% | -11.18% |
Average DrawdownAverage peak-to-trough decline | -18.82% | -10.91% | -7.91% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 9.22% | 5.31% | +3.91% |
Volatility
CI vs. NVS - Volatility Comparison
The Cigna Group (CI) has a higher volatility of 8.96% compared to Novartis AG (NVS) at 8.03%. This indicates that CI's price experiences larger fluctuations and is considered to be riskier than NVS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| CI | NVS | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 8.96% | 8.03% | +0.93% |
Volatility (6M)Calculated over the trailing 6-month period | 19.99% | 15.98% | +4.01% |
Volatility (1Y)Calculated over the trailing 1-year period | 33.60% | 21.51% | +12.09% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 28.61% | 19.18% | +9.43% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 30.75% | 19.69% | +11.06% |
Dividends
CI vs. NVS - Dividend Comparison
CI's dividend yield for the trailing twelve months is around 2.16%, less than NVS's 3.19% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
CI The Cigna Group | 2.16% | 2.19% | 2.03% | 1.64% | 1.35% | 1.74% | 0.02% | 0.02% | 0.02% | 0.02% | 0.03% | 0.03% |
NVS Novartis AG | 3.19% | 2.90% | 3.84% | 3.44% | 3.70% | 3.86% | 3.22% | 3.03% | 3.47% | 3.24% | 3.73% | 3.10% |
Financials
CI vs. NVS - Financials Comparison
This section allows you to compare key financial metrics between The Cigna Group and Novartis AG. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
CI vs. NVS - Profitability Comparison
CI - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jul 2026, The Cigna Group reported a gross profit of 0.00 and revenue of 68.49B. Therefore, the gross margin over that period was 0.0%.
NVS - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jul 2026, Novartis AG reported a gross profit of 10.07B and revenue of 13.52B. Therefore, the gross margin over that period was 74.4%.
CI - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jul 2026, The Cigna Group reported an operating income of 2.36B and revenue of 68.49B, resulting in an operating margin of 3.4%.
NVS - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jul 2026, Novartis AG reported an operating income of 4.24B and revenue of 13.52B, resulting in an operating margin of 31.3%.
CI - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jul 2026, The Cigna Group reported a net income of 1.65B and revenue of 68.49B, resulting in a net margin of 2.4%.
NVS - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jul 2026, Novartis AG reported a net income of 3.16B and revenue of 13.52B, resulting in a net margin of 23.3%.
Frequently Asked Questions
CI and NVS have a correlation of 0.28, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
CI has higher volatility (8.96%) compared to NVS (8.03%). In terms of maximum drawdown, CI dropped -84.34% vs NVS's -42.10%.
NVS currently has the higher Sharpe Ratio (1.63 vs -0.06), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for CI and NVS
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer